[1]
|
Sung, H., Ferlay, J., Siegel, R.L., Laversanne, M., Soerjomataram, I., Jemal, A. and Bray, F. (2021) Global Cancer Sta-tistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71, 209-249. https://doi.org/10.3322/caac.21660
|
[2]
|
国家肿瘤质控中心乳腺癌专家委员会, 中国抗癌协会乳腺癌专业委员会, 中国抗癌协会肿瘤药物临床研究专业委员会. 中国晚期乳腺癌规范诊疗指南(2022版) [J]. 中华肿瘤杂志, 2022, 44(12): 1262-1287.
|
[3]
|
Raman, D., Foo, C.H.J., Clement, M.-V. and Pervaiz, S. (2016) Breast Cancer: A Molecular and Redox Snapshot. Antioxidants & Redox Signaling, 25, 337-370. https://doi.org/10.1089/ars.2015.6546
|
[4]
|
Smith, R.E., Tran, K., Smith, C.C., et al. (2016) The Role of the Nrf2/ARE Antioxidant System in Preventing Cardiovascular Diseases. Diseases, 4, Article No. 34. https://doi.org/10.3390/diseases4040034
|
[5]
|
Xie, T.Y., Zahid, H., et al. (2023) Inhibitors of Keap1-Nrf2 Pro-tein-Protein Interaction Reduce Estrogen Responsive Gene Expression and Oxidative Stress in Estrogen Recep-tor-Positive Breast Cancer. Toxicology and Applied Pharmacology, 460, Article ID: 116375. https://doi.org/10.1016/j.taap.2023.116375
|
[6]
|
Akira, K., Moon-Il, K., et al. (2004) Oxidative Stress Sensor Keap1 Functions as an Adaptor for Cul3-Based E3 Ligase to Regulate Proteasomal Degradation of Nrf2. Molecular and Cellular Biology, 24, 7130-7139.
https://doi.org/10.1128/MCB.24.16.7130-7139.2004
|
[7]
|
Zhang, D.D., Lo, S.-C., Cross, J.V., Templeton, D.J. and Hannink, M. (2004) Keap1 Is a Redox-Regulated Substrate Adaptor Protein for a Cul3-Dependent Ubiquitin Ligase Complex. Molecular and Cellular Biology, 24, 10941-10953.
https://doi.org/10.1128/MCB.24.24.10941-10953.2004
|
[8]
|
Wang, X.-J., Sun, Z., Villeneuve, N.F., Zhang, S., Zhao, F., Li, Y.J., Chen, W.M., et al. (2008) Nrf2 Enhances Resistance of Cancer Cells to Chemotherapeutic Drugs, the Dark Side of Nrf2. Carcinogenesis, 29, 1235-1243.
https://doi.org/10.1093/carcin/bgn095
|
[9]
|
Aboulkassim, T., et al. (2023) A NRF2 Inhibitor Selectively Sensitizes KEAP1 Mutant Tumor Cells to Cisplatin and Gefitinib by Restoring NRF2-Inhibitory Function of KEAP1 Mutants. Cell Reports, 42, Article ID: 113104.
https://doi.org/10.1016/j.celrep.2023.113104
|
[10]
|
Xu, C.J., Huang, M.-T., Shen, G.X., Yuan, X.L., et al. (2006) Inhibition of 7, 12-Dimethylbenz(a)anthracene-Induced Skin Tumorigenesis in C57BL/6 Mice by Sulforaphane Is Medi-ated by Nuclear Factor E2-Related Factor 2. Cancer Research, 66, 8293-8296. https://doi.org/10.1158/0008-5472.CAN-06-0300
|
[11]
|
Khor, T.O., et al. (2008) Increased Susceptibility of Nrf2 Knockout Mice to Colitis-Associated Colorectal Cancer. Cancer Prevention Research (Philadelphia, Pa.), 1, 187-191. https://doi.org/10.1158/1940-6207.CAPR-08-0028
|
[12]
|
Becks, L., Prince, M., Burson, H., Christophe, C., Broadway, M., Itoh, K., et al. (2010) Aggressive Mammary Carcinoma Progression inNrf2 Knockout Mice Treated with 7,12-Dimethylbenz[a]anthracene. BMC Cancer, 10, Article No. 540. https://doi.org/10.1186/1471-2407-10-540
|
[13]
|
Frohlich, D.A., McCabe, M.T., Arnold, R.S. and Day, M.L. (2008) The Role of Nrf2 in Increased Reactive Oxygn Species and DNA Damage in Prostate Tumorigenesis. Oncogene, 27, 4353-4362. https://doi.org/10.1038/onc.2008.79
|
[14]
|
Taguchi, K. and Yamamoto, M. (2017) The KEAP1-NRF2 System in Cancer. Frontiers in Oncology, 7, Article No. 85.
https://doi.org/10.3389/fonc.2017.00085
|
[15]
|
马丽萍, 刘青杰, 田梅, 等. 辐射诱导p62/SQSTM1介导的细胞早衰研究进展[J]. 中华放射医学与防护杂志, 2020, 40(12): 968-972.
|
[16]
|
王秀君, 李欣, 唐修文. Nrf2通路在肿瘤化学预防中的研究进展[J]. 化学进展, 2013, 25(9): 1544-1552.
|
[17]
|
谢家祺, 刘毅, 霍楠楠. 乳腺癌中Nrf2/ARE信号通路异常表达的探讨[J]. 现代肿瘤医学, 2016, 24(7): 1065-1067.
|
[18]
|
Almeida, M., Soares, M., Ramalhinho, A.C., Moutinho, J.F., Breitenfeld, L. and Pereira, L. (2020) The Prognostic Value of NRF2 in Breast Can-cer Patients: A Systematic Review with Meta-Analysis. Breast Cancer Research and Treatment, 179, 523-532. https://doi.org/10.1007/s10549-019-05494-4
|
[19]
|
Mehrgou, A. and Akouchekian, M. (2016) The Importance of BRCA1 and BRCA2 Genes Mutations in Breast Cancer Development. Medical Journal of the Islamic Republic of Iran, 30, Article No. 369.
|
[20]
|
丁牧遥, 张倩, 袁胜涛, 等. NRF2信号通路在乳腺癌中的研究进展[J]. 中国细胞生物学学报, 2021, 43(10): 2085-2092.
|
[21]
|
Singh, B., et al. (2013) MicroRNA-93 Regulates NRF2 Expression and Is Asso-ciated with Breast Carcinogenesis. Carcinogenesis, 34, 1165-1172. https://doi.org/10.1093/carcin/bgt026
|
[22]
|
Yang, M.H., et al. (2011) MiR-28 Regulates Nrf2 Expression through a Keap1-Independent Mechanism. Breast Cancer Research and Treatment, 129, 983-991. https://doi.org/10.1007/s10549-011-1604-1
|
[23]
|
De Blasio, A., Di Fiore, R., Pratelli, G., et al. (2020) A Loop In-volving NRF2, miR-29b-1-5p and AKT, Regulates Cell Fate of MDA-MB-231 Triple-Negative Breast Cancer Cells. Journal of Cellular Physiology, 235, 629-637.
https://doi.org/10.1002/jcp.29062
|
[24]
|
Lee, S., Hallis, P.S., Jung, K., et al. (2019) Impairment of HIF-1α-Mediated Metabolic Adaption by NRF2-Silencing in Breast Cancer Cells. Redox Biology, 24, Article ID: 101210. https://doi.org/10.1016/j.redox.2019.101210
|
[25]
|
Mdkhana, B., et al. (2022) Role of Oxidative Stress in Angio-genesis and the Therapeutic Potential of Antioxidants in Breast Cancer. European Review for Medical and Pharmacolog-ical Sciences, 26, 4677-4692.
|
[26]
|
Kumar, H., Kumar, R.M., Bhattacharjee, D., et al. (2022) Role of Nrf2 Signaling Cascade in Breast Cancer: Strategies and Treatment. Frontiers in Pharmacology, 13, Article ID: 720076. https://doi.org/10.3389/fphar.2022.720076
|
[27]
|
Muz, B., de la Puente, P., Azab, F. and Azab, A.K. (2015) The Role of Hypoxia in Cancer Progression, Angiogenesis, Metastasis, and Resistance to Therapy. Hypoxia, 3, 83-92.
|
[28]
|
Oh, E.T., Kim, J.W., Kim, J.M., et al. (2016) NQO1 Inhibits Proteasome-Mediated Degradation of HIF-1α. Nature Communications, 7, Article No. 13593. https://doi.org/10.1038/ncomms13593
|
[29]
|
Toth, K.R., Warfel, A.N. and Mondal, D. (2017) Strange Bedfellows: Nuclear Factor, Erythroid 2-Like 2 (Nrf2) and Hypoxia-Inducible Factor 1 (HIF-1) in Tumor Hypoxia. Antioxidants, 6, Article No. 27.
https://doi.org/10.3390/antiox6020027
|
[30]
|
史晓燕, 李倩. Nrf2/ARE信号通路及其在乳腺癌中的研究进展[J]. 广西医学, 2018, 40(21): 2586-2588.
|
[31]
|
Zhang, H.-S., et al. (2019) Nrf2 Promotes Breast Cancer Cell Migration via Up-Regulation of G6PD/HIF-1α/Notch1 Axis. Journal of Cellular and Molecular Medicine, 23, 3451-3463. https://doi.org/10.1111/jcmm.14241
|
[32]
|
Aspenström, P. (2022) The Role of Fast-Cycling Atypical RHO GTPases in Cancer. Cancers, 14, Article No. 1961.
https://doi.org/10.3390/cancers14081961
|
[33]
|
Zhang, C., Wang, H.-J., Bao, Q.-C., Wang, L., Guo, T.-K., Chen, W.-L., et al. (2016) NRF2 Promotes Breast Cancer Cell Proliferation and Metastasis by Increasing RhoA/ROCK Path-way Signal Transduction. Oncotarget, 7, 73593-73606. https://doi.org/10.18632/oncotarget.12435
|
[34]
|
Li, D.F., Wang, H., Ding, Y., et al. (2018) Targeting the NRF-2/RHOA/ROCK Signaling Pathway with a Novel Aziridonin, YD0514, to Suppress Breast Cancer Progression and Lung Metastasis. Cancer Letters, 424, 97-108.
https://doi.org/10.1016/j.canlet.2018.03.029
|
[35]
|
Kartal-Yandim, M., Adan-Gokbulut, A. and Baran, Y. (2016) Molecular Mechanisms of Drug Resistance and Its Reversal in Cancer. Critical Reviews in Biotechnology, 36, 716-726. https://doi.org/10.3109/07388551.2015.1015957
|
[36]
|
Doyle, L.A., Yang, W., Abruzzo, L.V., Krogmann, T., Gao, Y., Rishi, A.K. and Ross, D.D. (1998) A Multidrug Resistance Transporter from Human MCF-7 Breast Cancer Cells. Proceedings of the National Academy of Sciences of the United States of America, 95, 15665-15670. https://doi.org/10.1073/pnas.95.26.15665
|
[37]
|
吴新刚, 彭姝彬, 黄谦. 乳腺癌耐药蛋白基因的转录调控机制[J]. 遗传, 2012, 34(12): 1529-1536.
|
[38]
|
Singh, A., Wu, H.L., Zhang, P., Happel, C., Ma, J.F. and Biswal, S. (2010) Expression of ABCG2 (BCRP) Is Regulated by Nrf2 in Cancer Cells That Confers Side Population and Chemoresistance Phenotype. Molecular Cancer Therapeutics, 9, 2365-2376. https://doi.org/10.1158/1535-7163.MCT-10-0108
|
[39]
|
张彦收, 唐甜甜, 周涛, 王新乐, 刘运江. BCRP和Ki-67与乳腺癌新辅助化疗疗效的关系[J]. 现代肿瘤医学, 2017, 25(16): 2588-2591.
|
[40]
|
张志鹏, 张喜平. 耐药基因的表达与乳腺癌化疗疗效的关系[J]. 内蒙古医科大学学报, 2019, 41(3): 328-331.
https://doi.org/10.16343/j.cnki.issn.2095-512x.2019.03.034
|
[41]
|
Sha, H., Zou, R., Lu, Y., et al. (2023) NBDHEX Re-Sensitizes Adriamycin-Resistant Breast Cancer by Inhibiting Glutathione S-Transferase pi. Cancer Medicine, 12, 5833-5845. https://doi.org/10.1002/cam4.5370
|
[42]
|
Tang, X., Wang, H., Fan, L., et al. (2011) Luteolin Inhibits Nrf2 Leading to Negative Regulation of the Nrf2/ARE Pathway and Sensitization of Human Lung Carcinoma A549 Cells to Therapeutic Drugs. Free Radical Biology and Medicine, 50, 1599-1609. https://doi.org/10.1016/j.freeradbiomed.2011.03.008
|
[43]
|
Sabzichi, M., Hamishehkar, H., Ramezani, F., et al. (2014) Luteolin-Loaded Phytosomes Sensitize Human Breast Carcinoma MDA-MB 231 Cells to Doxorubicin by Sup-pressing Nrf2 Mediated Signalling. Asian Pacific Journal of Cancer Prevention: APJCP, 15, 5311-5316. https://doi.org/10.7314/APJCP.2014.15.13.5311
|
[44]
|
Barbano, R., Muscarella, L.A., Pasculli, B., et al. (2013) Aberrant Keap1 Methylation in Breast Cancer and Association with Clinicopathological Features. Epigenetics, 8, 105-112. https://doi.org/10.4161/epi.23319
|
[45]
|
Tserga, A., Michalopoulos, N.V., Levidou, G., et al. (2012) Association of Aberrant DNA Methylation with Clinicopathological Features in Breast Cancer. Oncology Reports, 27, 1630-1638.
|
[46]
|
Ghareghomi, S., Habibi-Rezaei, M., et al. (2022) Nrf2 Modulation in Breast Cancer. Biomedicines, 10, Article No. 2668. https://doi.org/10.3390/biomedicines10102668
|
[47]
|
Jin, J.M., Qiu, S.P., Wang, P., Liang, X.H., Huang, F., Wu, H., et al. (2019) Cardamonin Inhibits Breast Cancer Growth by Repressing HIF-1α-Dependent Meta-bolic Reprogramming. Journal of Experimental & Clinical Cancer Research: CR, 38, Article No. 377. https://doi.org/10.1186/s13046-019-1351-4
|
[48]
|
Wei, Y.Z., Liu, D.Y., Jin, X.X., et al. (2016) PA-MSHA Inhibits the Growth of Doxorubicin-Resistant MCF-7/ADR Human Breast Cancer Cells by Downregulating Nrf2/p62. Cancer Medicine, 5, 3520-3531.
https://doi.org/10.1002/cam4.938
|
[49]
|
Dong, J., Li, Y., Xiao, H., et al. (2018) Cordycepin Sensitizes Breast Cancer Cells toward Irradiation through Elevating ROS Production Involving Nrf2. Toxicology and Applied Pharmacology, 364, 12-21.
https://doi.org/10.1016/j.taap.2018.12.006
|